China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non‐small cell lung cancer after two lines of chemotherapy

Cancer communications (London, England), 2019-06, Vol.39 (1), p.1-10 [Peer Reviewed Journal]

The Author(s) 2019 ;2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2523-3548 ;EISSN: 2523-3548 ;DOI: 10.1186/s40880-019-0383-7 ;PMID: 31221221

Full text available